ta-46
Recombinant proteinexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 19, 2018 (NCT04410809)
Timeline
Indications
Mechanism of action
FGFR3 agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650420 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05116046 | Phase 2 | Dec 7, 2021 | Pfizer |
| NCT05061277 | Phase 1 | Oct 14, 2021 | Pfizer |
| NCT04638153 | Phase 2 | Dec 2, 2020 | Pfizer |
| NCT04543344 | Phase 1 | Sep 17, 2020 | Pfizer |
| NCT04410809 | Phase 1 | Jan 19, 2018 | Pfizer |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 5 | 5 | 2 | 2018 |
1 organizations
Page 1 / 1